Why the study?
Venous thromboembolism has increased by 130% in pediatric patients over the past decade, and direct oral anticoagulants are anticipated to quickly replace parenteral anticoagulants, requiring clinicians to familiarize themselves with these therapies.
DOACs such as rivaroxaban and dabigatran are approved for pediatric VTE and offer the advantage of oral administration without therapeutic monitoring.
DOACs may simplify pediatric VTE management; leaves open need for more pediatric-specific long-term data.
Venous thromboembolism is a major hospital acquired complication in the pediatric population over the last two-decades, with a 130% increase in the past decade. Direct oral anticoagulants (DOACs) are a newer class of anticoagulant medication for the treatment and prophylaxis of VTEs that provide the primary advantages of an oral route of administration without a requirement to adjust dosing to achieve a therapeutic level. It is anticipated that these medications will quickly replace parenteral anticoagulants and clinicians should familiarize themselves with DOACs. In this article, we provide an overview of the pharmacological properties of DOACs, with a specific focus on rivaroxaban and dabigatran, which have been approved for use in pediatric patients. Each drug's characteristics are discussed along with data from their respective clinical trials.
No takes yet. Share an insight, caveat, or question.
Al‐Ghafry et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: